Want to see BCRX full AI Analyst Report?
BCRX Stock Chart & Stats
$9.34
$0.48(5.14%)
At close: 4:00 PM EDT
$9.34
$0.48(5.14%)
Day’s Range― - ―
52-Week Range$6.00 - $11.22
Previous CloseN/A
Volume1.53M
Average Volume (3M)5.32M
Market Cap
$2.64B
Enterprise Value$3.14K
Total Cash (Recent Filing)$352.57M
Total Debt (Recent Filing)$409.86M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Nov 04, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding255,535,110
10 Day Avg. Volume3,147,373
30 Day Avg. Volume5,315,058
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-13.74
Price to Sales (P/S)1.87
P/FCF Ratio5.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.88Price Target Upside123.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.3
Revenue Forecast (FY)$669.39M
Bulls Say, Bears Say
Bulls Say
Cash GenerationBioCryst’s recent operating and free cash flow turned strongly positive (2025 and TTM), producing hundreds of millions in cash. Durable cash generation underpins funding for commercialization, potential debt reduction, and milestone investments without constant equity dilution, improving long-term financial optionality.
Commercial Scale / ORLADEYOMulti-year revenue scaling and consistent ORLADEYO sales reflect durable market penetration in HAE. A growing installed base (~1,600 on therapy now) plus improving payer dynamics (paid rate ~84%) support predictable recurring revenues and a commercial footprint that can sustain long-term cash flows and fund lifecycle extensions.
Cost Discipline & BDManagement tightened op‑ex guidance, reported strong non‑GAAP profitability and secured an upfront license payment. This combination signals improved expense discipline and business‑development execution, which can sustainably reduce cash burn, shore up liquidity, and de‑risk commercialization while enabling outsourced R&D strategies.
Bears Say
Weak Capital StructurePersistently negative equity and substantial reported debt limit financial flexibility and increase refinancing and covenant risk over time. A strained capital structure reduces capacity for inorganic growth or sustained R&D spend and makes the company more sensitive to operational setbacks or adverse reimbursement shifts.
Profitability VolatilityLarge swings in net margin and sharp gross margin compression indicate unstable earnings quality and potential structural pressure on unit economics. Such volatility complicates long‑term planning, increases financing costs, and can erode reinvestable cash if adverse mix, pricing, or gross‑to‑net dynamics persist.
R&D Capability Shift & Pipeline TimingWinding down internal discovery and closing a research site reduces in‑house early discovery capacity, increasing reliance on partnerships and external sourcing. Coupled with long waits for key readouts (navenibart top line Q3‑2027; BCX17725 data end‑2026), this raises execution risk and concentrates future upside on fewer external bets.
BioCryst News
BCRX FAQ
What was BioCryst Pharmaceuticals’s price range in the past 12 months?
BioCryst Pharmaceuticals lowest stock price was $6.00 and its highest was $11.22 in the past 12 months.
What is BioCryst Pharmaceuticals’s market cap?
BioCryst Pharmaceuticals’s market cap is $2.64B.
When is BioCryst Pharmaceuticals’s upcoming earnings report date?
BioCryst Pharmaceuticals’s upcoming earnings report date is Nov 04, 2026 which is in 83 days.
How were BioCryst Pharmaceuticals’s earnings last quarter?
BioCryst Pharmaceuticals released its earnings results on Aug 05, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of $0.154 by $0.146.
Is BioCryst Pharmaceuticals overvalued?
According to Wall Street analysts BioCryst Pharmaceuticals’s price is currently Undervalued.
Does BioCryst Pharmaceuticals pay dividends?
BioCryst Pharmaceuticals does not currently pay dividends.
What is BioCryst Pharmaceuticals’s EPS estimate?
BioCryst Pharmaceuticals’s EPS estimate is 0.09.
How many shares outstanding does BioCryst Pharmaceuticals have?
BioCryst Pharmaceuticals has 255,535,110 shares outstanding.
What happened to BioCryst Pharmaceuticals’s price movement after its last earnings report?
BioCryst Pharmaceuticals reported an EPS of $0.3 in its last earnings report, beating expectations of $0.154. Following the earnings report the stock price went up 0.554%.
Which hedge fund is a major shareholder of BioCryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.88 (123.50% Upside)
$20.88 (123.50% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $100.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.02%
Trailing 12-Months
Company Description
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
BCRX Company Deck
BCRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial picture: strong comparable revenue growth (+45% total; ORLADEYO +10% YoY), solid cash balance (~$350M+) and non-GAAP profitability ($113.2M), successful enrollment milestones (navenibart pivotal study completed ahead of schedule), and an initiated pediatric launch with encouraging early demand (47 prescriptions). Management also reinforced financial discipline, tightened operating cost guidance, and secured a €55.7M upfront license payment. Offsetting items include a prior manufacturing delay for pediatric pellets (now shipping), a strategic wind-down of internal discovery and Birmingham facility closure that reduces in-house R&D capacity, continued competition from new injectables, and timing uncertainty for several material clinical data readouts (navenibart top line in Q3 2027; BCX17725 POC by end-2026). On balance, the positive financial and commercial momentum and clear cost discipline outweigh the challenges and transition risks.View all BCRX earnings summariesBCRX Stock 12 Month Forecast
Average Price Target
$20.88
▲(123.50% Upside)
Technical Analysis
Ownership Overview
1.47% Insiders
15.39% Mutual Funds
4.80% Other Institutional Investors
58.54% Public Companies and Individual Investors